Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01507558 · ClinicalTrials.gov registry record · NA

Dexamethasone Infusion to the Adventitia to Enhance Clinical Efficacy After Femoropopliteal Revascularization

A NA study of Peripheral Arterial Disease, sponsored by University of California, San Francisco.

Completed
Registry status
NA
Development phase
22
Enrollment target
2
Study locations

NCT01507558: Completed NA study of Peripheral Arterial Disease, sponsored by University of California, San Francisco.

NCT01507558 is a NA study of Peripheral Arterial Disease that has completed, run by University of California, San Francisco. The registered enrollment target is 22 participants, below the 4,206-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01507558, a NA study of Peripheral Arterial Disease, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
NA
Development phase
22 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to test if dexamethasone, an anti-inflammatory medication approved by the US Food and Drug Administration (FDA), can be injected safely into the tissue around the blood vessel wall at the time of an angioplasty or atherectomy.

Primary Outcome

Freedom from death, vessel dissection, thrombosis or extravasation at 30 days post-procedure.

Interventions

  • PROCEDURE Administration of dexamethasone to SFA/popliteal adventitia

Study Locations (2)

California

  • San Francisco VA Medical Center - San Francisco
  • University of California, San Francisco Medical Center - San Francisco

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2010-12
Est. Completion 2016-12
Phase NA

What the finished NCT01507558 record still lists

NCT01507558 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 4,206-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 1 intervention - of which Administration of dexamethasone to SFA/popliteal adventitia is the first listed.

NCT01507558 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT01507558 about?

NCT01507558 is a clinical study titled "Dexamethasone Infusion to the Adventitia to Enhance Clinical Efficacy After Femoropopliteal Revascularization". The purpose of this study is to test if dexamethasone, an anti-inflammatory medication approved by the US Food and Drug Administration (FDA), can be injected safely into the tissue around the blood vessel wall at the time of an angioplasty or atherectomy.

What is the current status of trial NCT01507558?

This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2010-12. Estimated completion is 2016-12.

What conditions does trial NCT01507558 study?

This clinical trial studies the following conditions: Peripheral Arterial Disease.

What interventions are being tested in trial NCT01507558?

The interventions under investigation include: Administration of dexamethasone to SFA/popliteal adventitia (PROCEDURE).

Who is sponsoring clinical trial NCT01507558?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01507558 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Peripheral Arterial Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01507558's enrollment target sits among peer trials

22 64th of 79 higher than 15 of 79 other Peripheral Arterial Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Peripheral Arterial Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01507558, the US trial registry maintained by the National Library of Medicine. NCT01507558 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.